Oppenheimer raised the firm’s price target on TransMedics to $105 from $92 and keeps an Outperform rating on the shares. The firm notes TransMedics reported Q4 revenues of $81.2M, handily beating Oppenheimer and consensus’ estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TMDX:
